Anthony Hunt sold $3.1M of RGEN
director at REPLIGEN CORP. 20,000 shares at an average of $154.61, traded Nov 13, 2025, filed Nov 14, 2025.
Score components
- +15RoleDirector
- +25Trade size$3.1M at market
- +5Share of holdings soldSold 20% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-283092, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 13, 2025 | SOpen-market sale Common Stock | -1,784 | $151.01 | $269k | 98,959 | Nov 14, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock | -2,100 | $152.17 | $320k | 96,859 | Nov 14, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock | -2,923 | $153.14 | $448k | 93,936 | Nov 14, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock | -2,500 | $154.32 | $386k | 91,436 | Nov 14, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock | -3,000 | $155.45 | $466k | 88,436 | Nov 14, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock | -5,737 | $156.22 | $896k | 82,699 | Nov 14, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock | -1,956 | $157.11 | $307k | 80,743 | Nov 14, 2025 |
| Nov 13, 2025 | MOption exercise Common Stock | +2,952 | $33.87 | $100k | 83,695 | Nov 14, 2025 |
| Nov 13, 2025 | MOption exercise Stock Option (Right to Buy)derivative | +2,952 | $0.00 | $0 | 14,760 | Nov 14, 2025 |
Related signals
Other insiders at REPLIGEN CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | REPLIGEN CORP | Olivier Loeillot Chief Executive Officer | $1.0M 5,535 shares | -12% | |
| 20Weak | REPLIGEN CORP | Olivier Loeillot Chief Executive Officer | $2.5M 12,946 shares | -23% | |
| 20Weak | REPLIGEN CORP | Olivier Loeillot Chief Executive Officer | $977k 5,426 shares | -10% | |
| 23Weak | REPLIGEN CORP | Olivier Loeillot Chief Executive Officer | $504k 3,035 shares | -6% | |
| 21Weak | RGENsell REPLIGEN CORP | Karen A Dawes director | $44k 275 shares | -0% | |
| 50Moderate | REPLIGEN CORP | Olivier Loeillot Chief Executive Officer | $1.2M 7,041 shares | -16% | |
| 50Moderate | REPLIGEN CORP | James Bylund Chief Operating Officer | $331k 2,191 shares | -9% | |
| 25Weak | REPLIGEN CORP | Anthony Hunt director | $3.9M 25,000 shares | -20% | |
| 30Weak | RGENsell REPLIGEN CORP | Anthony Hunt director | $3.5M 29,111 shares | -22% | |
| 53Moderate | RGENbuy REPLIGEN CORP | Martin D Madaus director | $202k 1,800 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.